ADC Therapeutics (Group)

https://www.adctherapeutics.com

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. *

	Start	2012-03-26 established pred
	Today	ADC Therapeutics S.A. (NYSE: ADCT)
	Predecessor	ADC Therapeutics S.à.r.l. (ADCT)
	Industry	antibody-drug conjugates (ADC) technology
	Industry 2	cancer drug

	Street	3B Route de la Corniche
	City	1066 Epalinges VD
	Tel	+41-21-653-0200
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2021-12-31)
	Currency	USD
	Annual sales	33,917,000 (revenue, total, consolidated (2021) 2021-12-31)
	Profit	-230,026,000 (2021-12-31)
	Cash	466,544,000 (2021-12-31)

		* Document for »About Section«: ADC Therapeutics S.A.. (6/13/22). "Press Release: ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer". Lausanne.

		Record changed: 2023-07-23

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for ADC Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)